Q3 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Conclusions
Appendix
Innovation: Clinical trials
Net debt increased by USD 3.6bn mainly due to dividends
and share buybacks, partially offset by FCF
USD bn
-7.2
-7.3
-7.3
Dec 31, 2022
Dividends
Treasury share
transactions, net
-2.9
M&A/Intangible
assets
transactions, net
-3.6
References
Abbreviations
FINANCIAL PROFILE
-10.8
-0.1
3.0
11.0
Free Cash Flow
Others
Net debt Sandoz 1
Sep 30, 2023
1. Reflects USD 0.6bn cash and USD 3.7bn of financial debts of Sandoz as of Sep 30, 2023. In addition, on Oct 2, 2023, through a series of intercompany transactions in connection with the distribution (spin-off) of the Sandoz business to
Novartis AG shareholders, USD 38m was paid in cash from a Novartis affiliate to the Sandoz business. Including this transaction, Sandoz cash on Oct 2, 2023, amounted to USD 0.7bn.
42 Investor Relations | Q3 2023 Results
U NOVARTIS | Reimagining MedicineView entire presentation